NUVB

NUVB

USD

Nuvation Bio Inc. Class A Common Stock

$1.810-0.390 (-17.727%)

Echtzeitkurs

Healthcare
Biotechnologie
Vereinigte Staaten

Kursdiagramm

Loading Chart...

Schlüsselkennzahlen

Marktkennzahlen
Unternehmensfundamentaldaten
Handelsstatistiken

Marktkennzahlen

Eröffnung

$2.200

Hoch

$2.230

Tief

$1.800

Volumen

6.43M

Unternehmensfundamentaldaten

Marktkapitalisierung

615.9M

Branche

Biotechnologie

Land

United States

Handelsstatistiken

Durchschnittliches Volumen

4.17M

Börse

NYQ

Währung

USD

52-Wochen-Spanne

Tief $1.54Aktuell $1.810Hoch $3.97

Ähnliche Nachrichten

Analyst Upgrades

Wedbush Maintains Outperform on Nuvation Bio, Maintains $5 Price Target

Wedbush analyst David Nierengarten maintains Nuvation Bio with a Outperform and maintains $5 price target.

Mehr anzeigen
Wedbush Maintains Outperform on Nuvation Bio, Maintains $5 Price Target
BusinessWire

U.S. Food and Drug Administration Approves Nuvation Bio's IBTROZI™ (taletrectinib), a Next-Generation Oral Treatment for Advanced ROS1-Positive Non-Small Cell Lung Cancer

Approval follows Priority Review and is supported by the robust TRUST clinical program, in which IBTROZI treatment demonstrated high, durable response rates and brain-penetrant efficacy across different lines of

Mehr anzeigen
U.S. Food and Drug Administration Approves Nuvation Bio's IBTROZI™ (taletrectinib), a Next-Generation Oral Treatment for Advanced ROS1-Positive Non-Small Cell Lung Cancer
Analyst Upgrades

JMP Securities Reiterates Market Outperform on Nuvation Bio, Maintains $6 Price Target

JMP Securities analyst Silvan Tuerkcan reiterates Nuvation Bio with a Market Outperform and maintains $6 price target.

Mehr anzeigen
JMP Securities Reiterates Market Outperform on Nuvation Bio, Maintains $6 Price Target